24-058 Phase II
A Phase 1/2a Study of IMM-6-415 in Participants with Advanced or Metastatic Malignancies Harboring RAS or RAF Oncogenic Mutations
A Phase 1/2a Study of IMM-6-415 in Participants with Advanced or Metastatic Malignancies Harboring RAS or RAF Oncogenic Mutations
A Phase 1a Open-Label, Dose-Escalation, and a Phase 2 Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of ST-067 Administered Subcutaneously as Monotherapy in Patients with Relapsed or Refractory Solid Tumors
A Phase 1a/1b Study to Evaluate the Safety and Tolerability of STK-012 as a Single Agent and in Combination Therapy in Subjects With Selected Advanced Solid Tumors
A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma
A Phase 3 Trial of Fianlimab (Anti-LAG-3) and Cemiplimab Versus Pembrolizumab in the Adjuvant Setting in Patients With Completely Resected High-risk Melanoma
A Phase I, Open-label, Multi-center Study of KFA115 as a Single Agent and in Combination with Pembrolizumab in Patients with Select Advanced Cancers
A Phase I/II, multi-center, open label study of DYP688 in patients with metastatic uveal melanoma (MUM) and other GNAQ/11 mutant melanomas
A Phase II Study of Core Needle Biopsy and Cryoablation of an Enlarging Tumor in Patients With Advanced Melanoma Receiving Post-progression Dual Immune Checkpoint Inhibitor Therapy
A Phase II study of PD-1 blockade with or without LAG-3 inhibition in combination with infliximab for the treatment of metastatic melanoma and prevention of adverse events
A Phase II Study of the Interleukin-6 Receptor Blocking Antibody Sarilumab in Combination with Ipilimumab, Nivolumab and Relatilimab in Patients with Unresectable Stage III or Stage IV Melanoma